Confidence Region Approach for Assessing Bioequivalence and Biosimilarity Accounting for Heterogeneity of Variability
For approval of generic drugs, the FDA requires that evidence of bioequivalence in average bioequivalence in terms of drug absorption be provided through the conduct of a bioequivalence study. A test product is said to be average bioequivalent to a reference (innovative) product if the 90% confidenc...
Saved in:
Main Authors: | Jianghao Li, Shein-Chung Chow |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Probability and Statistics |
Online Access: | http://dx.doi.org/10.1155/2015/298647 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative study on the bioavailability and bioequivalence of rifapentine capsules in humans
by: Ying Qi, et al.
Published: (2025-01-01) -
Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product
by: Neungseon Seo, et al.
Published: (2024-11-01) -
CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®
by: S. M. Alekseev, et al.
Published: (2015-04-01) -
Pimobendan oral solution is bioequivalent to pimobendan chewable tablets in beagle dogs
by: Olaf Kuhlmann, et al.
Published: (2025-01-01) -
Bioequivalence study of fluticasone propionate nebuliser suspensions in healthy Chinese subjects
by: Feng Cheng, et al.
Published: (2025-01-01)